Cancer therapy and cardiovascular risk: focus on bevacizumab

Panagiota Economopoulou¹
Athanasios Kotsakis²
Ioannis Kapiris³
Nikolaos Kentepozidis³
¹Medical Oncology Unit, 2nd Department of Internal Medicine, Attikon University Hospital, Haidari, Athens, ²Department of Medical Oncology, University Hospital of Heraklion, Crete, ³251 Airforce General Hospital, Department of Medical Oncology, Athens, Greece

Correspondence: Panagiota Economopoulou
Medical Oncology Unit, 2nd Department of Internal Medicine, Attikon University Hospital, National Kapodistrian University of Athens, 1st Rimini St, 12462, Haidari, Athens, Greece
Tel +30 210 583 1655
Fax +30 210 583 1690
Email panagiota_oiko@hotmail.com

Abstract: Recognition and management of treatment-related cardiovascular toxicity, defined as either an acute cardiac event or a chronic condition, has been tightly integrated into routine cancer care and has become an important component in treatment selection. Several chemotherapeutic agents, such as anthracyclines, are traditionally characterized as cardiotoxic, but cardiovascular adverse events are also associated with commonly used molecular targeted therapies. In the past decade, bevacizumab, a monoclonal humanized antibody against vascular endothelial growth factor, has been introduced in the treatment of a variety of metastatic malignancies. Despite its efficacy, bevacizumab has been associated with significant risk of cardiovascular complications, such as hypertension, cardiac ischemia, and congestive heart failure. This review will focus on the cardiovascular toxicity of bevacizumab, providing the latest evidence on the incidence, clinical spectrum, risk factors, and responsible mechanisms.

Keywords: bevacizumab, cardiovascular toxicity, hypertension

Introduction
Systemic anticancer treatments can have detrimental effects on the cardiovascular system, either by exerting their own toxic effects or by augmenting side effects of other drugs.¹ As the development of novel drugs evolves, cancer survival has improved and cardiac toxicity caused by various anticancer agents has greater potential impact on long-term outcomes. The emerging field of cardio-oncology has developed strategies to minimize cardiovascular toxicity and prevent long-term effects.

Cardiotoxicity includes acute events, such as arrhythmias, myocardial ischemia, vasospastic and thromboembolic ischemia, pericarditis and/or myocarditis-like syndromes, and chronic conditions, such as left ventricular (LV) dysfunction (LVD) with or without overt congestive heart failure (CHF), arterial hypertension (HTN), and QTc prolongation.² More specifically, according to the Cardiac Review and Evaluation Committee, LVD is characterized by the following: 1) a decrease in cardiac LV ejection fraction (LVEF) that is either global or more severe in the septum; 2) symptoms of CHF; 3) signs of CHF, including but not limited to S3 gallop, tachycardia, or both; and 4) decreases in LVEF from baseline of at least 5% to below 55% with associated signs or symptoms of CHF, or at least 10% to below 55% without associated signs or symptoms.³

Anticancer drugs that induce cardiotoxicity have been divided into two categories depending on the reversibility of myocardial damage.⁴ Type I agents directly cause cell death leading to irreversible myocyte destruction and clinical CHF. These include traditional anticancer therapies, such as anthracyclines, alkylating agents, and...
antimicrotubule agents. On the other hand, type II agents alter normal cellular function by affecting the mitochondrial system and reducing protein synthesis, which is reversible once the drug is discontinued. Type II cardiotoxicity was first described with trastuzumab, although more recently, it has been associated with newer targeted therapies, including vascular endothelial growth factor (VEGF) inhibitors and tyrosine kinase inhibitors.5

Bevacizumab is a humanized monoclonal antibody against the VEGF-A ligand that binds to its circulating target, altering the kinetics of ligand binding to endothelial cells and downregulating angiogenesis.6 It has been approved by the European Medicines Agency and/or by the United States Food and Drug Administration, and it is the first- or second-line chemotherapy for the treatment of many advanced solid tumors, including colorectal cancer (CRC), non-small-cell lung cancer (NSCLC), breast cancer, glioblastoma, renal cell cancer (RCC), ovarian cancer, and cervical cancer.7–14 Although the efficacy of bevacizumab has been demonstrated in many clinical trials, its use has been associated with many cardiovascular events, such as high-grade HTN and thromboembolism.15

The aim of this review is to summarize and discuss the available evidence on the cardiovascular toxicity of anticancer systemic therapies, with special attention paid to the recently recognized adverse effects of bevacizumab. In the era of personalized medicine, knowing the potential cardiovascular risks of anticancer agents might influence the optimal choice of treatment and allow for the establishment of prevention strategies.

**Cardiovascular toxicity of bevacizumab**

In several trials evaluating the efficacy and toxicity of bevacizumab, its use has been predominantly complicated with HTN, CHF, and thromboembolic events. The incidence of the cardiovascular toxicity of bevacizumab in important clinical trials is summarized in Table 1.

**HTN**

HTN is a common adverse event occurring in patients treated with bevacizumab, with an overall incidence of 4%–35% reported in clinical trials.9,10,16–17 This variability might be attributed to the different selection criteria used in clinical trials (eg, the age of the patients included), as well as to differences in the definition of HTN. The mechanism of bevacizumab therapy-related HTN is not fully understood. It has been proposed that VEGF inhibition decreases nitric oxide production in the endothelium, leading to vasoconstriction and, therefore, to increased peripheral vascular resistance and blood pressure (BP).18 Reduced levels of nitric oxide promotes the expression of plasminogen-activator inhibitor 1 (PAI-1), resulting in exacerbation of HTN. Furthermore, VEGF inhibition has been associated with cholesterol embolization syndrome, which refers to embolization of the contents of an atherosclerotic plaque from a proximal large-caliber artery to distal small arteries. This leads to a multitude of small emboli occurring over time, causing mechanical plugging of the arteries and HTN.19

In Phase I trials, bevacizumab was safely administered at a dose up to 10 mg/kg without dose-limiting toxicities, but mild increases in BP were observed at higher dose levels tested.20 In Phase II trials assessing the efficacy and toxicity of the drug, severe HTN (grade 3 and 4) was reported in 9%–15% of patients.21–23 On the other hand, in Phase II trials that evaluated bevacizumab in combination with other chemotherapy agents or targeted therapies, grade 3 or 4 HTN ranged from 0%–19%.24–35 As expected, patients who crossed over from the control arm to the bevacizumab arm also displayed HTN. The median interval from initiation of bevacizumab to the development of HTN is approximately 4.6–6 months. In the majority of Phase III trials that led to the approval of bevacizumab, HTN was statistically significant more frequently in the bevacizumab-treated arm.5,11,12,14 In a landmark Phase III trial that assessed the efficacy of bevacizumab alone or in combination with irinotecan in recurrent glioblastoma, HTN was more frequent in the bevacizumab alone arm.12 In a recent meta-analysis of randomized controlled trials, the addition of bevacizumab to chemotherapy was associated with a statistically significant increase in high BP. Interestingly, patients with RCC and breast cancer who received the drug at a dose of 5 mg/kg weekly had a higher risk of developing HTN.36

Bevacizumab-related HTN can develop at any time during treatment, and the data suggest that there is a dose relationship.37 More specifically, the risk of HTN is increased by three times with low doses and 7.5 times with high doses of bevacizumab.38 Most patients who developed HTN in clinical trials were treated with antihypertensive medication and continued bevacizumab. This is particularly important, since there is a clear association between the efficacy of and duration of exposure to bevacizumab.39 However, HTN resistant to medication might lead to discontinuation of bevacizumab in 1.7% of patients.1 Single cases of hypertensive crisis with encephalopathy and subarachnoid hemorrhage have also been reported.1
Interestingly, several clinical trials have shown that the development of bevacizumab-related HTN is a predictive marker for clinical outcomes. Reported data from various malignancies, such as metastatic breast, metastatic colorectal, non-small-cell, and ovarian cancer, as well as malignant glioblastoma, clearly indicate an improved progression-free survival and/or overall survival in patients who develop HTN as a drug side effect.\textsuperscript{40–45} The responsible underlying mechanism has not yet been clarified.

The exact factors that predispose an individual to bevacizumab-induced HTN have not been established. However, several risk factors associated with VEGF inhibitor (VEGFI)-related HTN have been identified, including a previous history of HTN, age >65 years, smoking, and possibly hypercholesterolemia.\textsuperscript{56}

For the treatment of bevacizumab-related HTN, standard hypertensive medications are used, according to the European Society of Cardiology (ESC) and European Society for Medical Oncology (ESMO) guidelines.\textsuperscript{47–50} It is important not to withdraw treatment early, but rather to implement active antihypertensive medication with the objective of obtaining a BP <140/90 mmHg. A combination of antihypertensive drugs might be required, and close monitoring of BP is mandatory. Angiotensin-converting enzyme (ACE) inhibitors are suggested as the first-line treatment, since they have been shown to prevent proteinuria (also induced by bevacizumab) and PAI-1 expression.\textsuperscript{51} Furthermore, in vivo studies have demonstrated that ACE inhibitors increase the release of the natural vasodilator nitric oxide, overcoming the proposed mechanism of bevacizumab-associated HTN.\textsuperscript{52} However, they seem to have suboptimal BP-lowering effects when HTN is severe. In that case, calcium channel blockers are particularly effective, possibly because they reduce vascular smooth muscle cell contraction in vessels that are hypercontractile due to VEGFI-induced impairment of nitric oxide signaling. Only dihydropyridine calcium channel blockers, such as amlodipine or nifedipine, should be used, because nondihydropyridine calcium channel blockers, such as diltiazem or verapamil, inhibit cytochrome P450 3A4, which metabolizes VEGFIs, thus leading to potentially high levels of plasma bevacizumab.\textsuperscript{53} Discontinuation of bevacizumab may be applicable if systolic BP is >200 mmHg or if diastolic BP is >100 mmHg, or in cases of hypertensive crisis.

**CHF**

Approximately 2%–4% of patients treated with bevacizumab will develop CHF.\textsuperscript{1} Predisposing factors include previous therapy with cardiotoxic chemotherapy drugs, such as anthracyclines\textsuperscript{24} and capecitabine,\textsuperscript{10} as well as irradiation to the mediastinum.\textsuperscript{1} The main mechanism responsible for bevacizumab-associated CHF is suggested to be uncontrolled HTN, leading to LV hypertrophy.\textsuperscript{7,6} On the other hand, animal studies have demonstrated that normal cardiac growth and preserved contractile function are associated with enhanced coronary angiogenesis; thus, disruption of coordinated tissue growth and angiogenesis in the heart, induced by bevacizumab, contributes to progression from adaptive cardiac hypertrophy to heart failure (HF).\textsuperscript{55} Furthermore, angiogenesis plays a key role in the normal adaptive response to pressure overload. A study that has utilized strategies mimicking the mechanism of bevacizumab have shown that pressure overload resulted in a reduction of contractile dysfunction and eventually decompensated HF.\textsuperscript{54}

CHF has mainly been reported in clinical trials assessing the efficacy and toxicity of bevacizumab in breast cancer patients. This might be related to the fact that the majority of patients with metastatic breast cancer have been previously treated with cardiotoxic drugs, such as anthracyclines. In a Phase III breast cancer trial, anthracycline treatment preceded all cases of cardiomyopathy and HF (2.6% of patients).\textsuperscript{56} In another study,\textsuperscript{56} LVD was reported in <1% of patients. On the contrary, no cases of HF were reported in colorectal or lung cancer trials evaluating bevacizumab.\textsuperscript{7,57} In a recent retrospective study that included 6,937 patients aged ≥65 years with CRC, no association between bevacizumab and CHF or cardiac death was observed.\textsuperscript{58} These results suggest that the main predisposing factor for the development of CHF in patients receiving bevacizumab is not advanced age, but rather previous therapy with cardiotoxic drugs.

Cancer patients on bevacizumab therapy who develop HF should be treated according to guidelines proposed by the ESC and ESMO.\textsuperscript{59,59} Patients developing asymptomatic LVEF dysfunction of <50% during bevacizumab therapy should be referred to a cardiologist and receive ACE inhibitors. Bevacizumab should be stopped until improvement and normalization of LVEF. Patients with more advanced stages of HF should receive a combination of ACE inhibitors and beta blockers, unless contraindicated. As HF worsens, additional medication, such as diuretics, is required.\textsuperscript{60} All patients with HF should undergo coronary angiography to exclude coronary artery disease.

**Arterial thromboembolic events (ATEs)**

Combination treatment with bevacizumab and chemotherapy is associated with an increased risk of arterial thromboembolism (myocardial and cerebrovascular events).
Table 1 Cardiac toxicity of BEV in important clinical trials

<table>
<thead>
<tr>
<th>Phase/regimen</th>
<th>HTN Grades 3 and 4</th>
<th>CHF Grades 3 and 4</th>
<th>ATEs Grades 3 and 4</th>
<th>VTEs Grades 3 and 4</th>
<th>Disease setting/number of patients</th>
<th>Efficacy results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>I/BEV up to 10 mg/kg</td>
<td>Mild HTN in higher doses</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>Metastatic cancers/25</td>
<td>Safely administered at a dose up to 10 mg/kg without dose-limiting toxicity</td>
<td>Gordon et al.10</td>
</tr>
<tr>
<td>II/BEV 5 mg/kg or 10 mg/kg q2w</td>
<td>15%</td>
<td>0%</td>
<td>4%</td>
<td>2%</td>
<td>Unresectable HCC/46</td>
<td>PFS: 6.9 months; 1-year OS: 53%</td>
<td>Siegel et al.21</td>
</tr>
<tr>
<td>II/BEV 15 mg/kg q3w</td>
<td>9.1% (31.8% any grade)</td>
<td>0%</td>
<td>9.2%</td>
<td>2.3%</td>
<td>Platinum-resistant epithelial ovarian cancer or peritoneal serous carcinoma/44</td>
<td>PFS: 4.4 months; median OS: 10.7 months</td>
<td>Cannistra et al.22</td>
</tr>
<tr>
<td>II/BEV 15 mg/kg q3w</td>
<td>9.6%</td>
<td>0%</td>
<td>0%</td>
<td>3.2%</td>
<td>Persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer/44</td>
<td>PFS: 4.7 months; clinical response: 21%; OS: 17 months</td>
<td>Burger et al.23</td>
</tr>
<tr>
<td>II/BEV 15 mg/kg, doxorubicin 75 mg/m2 q3w</td>
<td>0%</td>
<td>11.7% (35.2% any grade)</td>
<td>0%</td>
<td>5.8%</td>
<td>Metastatic soft tissue sarcoma/17</td>
<td>12% PR; 65% SD</td>
<td>D’Adamo et al.24</td>
</tr>
<tr>
<td>II/BEV 5 mg/kg, FOLFOX4 q2w</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>Metastatic colorectal cancer/53</td>
<td>TTP: 11 months; 3-year OS: 58.3%</td>
<td>Emmanouilides et al.25</td>
</tr>
<tr>
<td>I–II/BEV 10 mg/kg q2w, erlotinib 150 od, imatinib 400 od</td>
<td>7%–8%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>Metastatic renal cell cancer/94</td>
<td>PFS: 8.9 months; OS: 17.2 months</td>
<td>Hainsworth et al.26</td>
</tr>
<tr>
<td>II/BEV 10 mg/kg d1 and d15; gemcitabine 1,000 mg/m2 d1, d8, and d15 q28d</td>
<td>19%</td>
<td>0%</td>
<td>0%</td>
<td>14%</td>
<td>Advanced pancreatic cancer/52</td>
<td>PFS: 5.4 months; OS: 8.8 months</td>
<td>Kindler et al.27</td>
</tr>
<tr>
<td>II/BEV q2w, mFOLFOX6 q2w, erlotinib 150 mg od</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>Metastatic colorectal cancer/35</td>
<td>RR: 34%</td>
<td>Meyerhardt et al.28</td>
</tr>
<tr>
<td>II/BEV 10 mg/kg d1 and d15, docetaxel 35 mg/m2 d1, d8, and d15 q28d</td>
<td>4%, 96% grade I</td>
<td>0%</td>
<td>0%</td>
<td>7%; 92% grade I</td>
<td>Metastatic breast cancer/27</td>
<td>PFS: 7.5 months; ORR: 52%</td>
<td>Ramaswamy et al.29</td>
</tr>
<tr>
<td>II/RT, 5-FU 600 mg/m2, hydroxyurea 500 mg bd, BEV 10 mg/kg q2w</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>Locally advanced head and neck cancer/26</td>
<td>2-year OS: 58% with BEV; 89% without BEV</td>
<td>Salama et al.30</td>
</tr>
<tr>
<td>II/RT, BEV 10 mg/kg q2w, cisplatin 33 mg/m2 d1–d3 w1 and w5, erlotinib od</td>
<td>0% (13% grade 2)</td>
<td>0%</td>
<td>3.4%</td>
<td>0%</td>
<td>Stage II/IV head and neck cancer/29</td>
<td>3-year OS: 86%</td>
<td>Yoo et al.31</td>
</tr>
<tr>
<td>II/IMRT, BEV 15 mg/kg q3w, cisplatin 50 mg/m2 d1–d2 q3w</td>
<td>0% (31 grades I and 2)</td>
<td>0%</td>
<td>0%</td>
<td>7%</td>
<td>Locally advanced head and neck cancer/42</td>
<td>2-year PFS: 75.9%; 2-year OS: 88%</td>
<td>Fury et al.32</td>
</tr>
<tr>
<td>Dosage</td>
<td>Bevacizumab-related Cardiac Toxicity</td>
<td>Treatment</td>
<td>3-year PFS:</td>
<td>3-year OS:</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------</td>
<td>-----------</td>
<td>-------------</td>
<td>-------------</td>
<td>-----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II/RT, BEV 5 mg/kg q2w, docetaxel 20 mg/m² weekly</td>
<td>0% (3%) grade I</td>
<td>Locally advanced head and neck cancer/30</td>
<td>62%</td>
<td>68%</td>
<td>Yao et al.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II, BEV 15 mg/kg q3w, cetuximab 250 mg/m² weekly</td>
<td>7%</td>
<td>Recurrent or metastatic head and neck cancer/48</td>
<td>Median PFS: 2.8 months; median OS: 7.5 months</td>
<td>Argriris et al.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–III/BEV up to 15 mg/kg, erlotinib 150 mg daily</td>
<td>0%</td>
<td>Recurrent or metastatic head and neck cancer/48</td>
<td>Median PFS: 2.8 months; median OS: 7.5 months</td>
<td>Cohen et al.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II/FOLFOX4 + BEV 10 mg/kg q2w, FOLFOX q2w, or BEV q2w</td>
<td>7.3% (BEV) 5.2% (FOLFOX/BEV) 0.4% (BEV)</td>
<td>Metastatic colorectal cancer/829</td>
<td>FOLFOX/BEV: median PFS: 7.3 months; median OS: 12.9 months</td>
<td>Giontonio et al.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II/Carboplatin 6 AUC, paclitaxel 200 mg/m² q2w</td>
<td>7%</td>
<td>Stage IIIB/IV NSCLC/878</td>
<td>Median OS: 12.3 months versus 10.3 months</td>
<td>Sandler et al.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II/Paclitaxel 90 mg/m² d1, d8, d15; BEV 15 mg/kg d1, d15 q4w</td>
<td>14.8% 0.8% 1.9% 1.7%</td>
<td>Metastatic breast cancer/722</td>
<td>PFS: 11.8 months versus 5.9 months with the addition of BEV</td>
<td>Miller et al.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II/Carboplatin 4 AUC, gemcitabine 1,000 mg/m² d1 and d8; BEV 15 mg/kg q3w</td>
<td>17.4% 1.2% 2.8% 4%</td>
<td>Platinum-sensitive ovarian/primary peritoneal cancer/484</td>
<td>6-month PFS: 42.6% (BEV) versus 50.3% (BEV/irinotecan)</td>
<td>Friedman et al.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II/BEV 10 mg/kg ± irinotecan 340 mg/m² or 125 mg/m² q2w</td>
<td>8.3% (BEV); 1.3% (BEV/irinotecan) 0% 2.4% (BEV); 2.5% (BEV/irinotecan) 0% 3.6% (BEV); 8.9% (BEV/irinotecan) 0%</td>
<td>Recurrent glioblastoma/167</td>
<td>Median OS: 18.3 (BEV + IrNAs) versus 17.4 months</td>
<td>Rini et al.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II/BEV 10 mg/kg q2w ± IrNAs</td>
<td>28% &lt;1% 1% 4%</td>
<td>Metastatic renal cell carcinoma/732</td>
<td>Median OS: 17 months (BEV + chemotherapy) versus 13.3 months (chemotherapy alone)</td>
<td>Tewari et al.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II/Cisplatin 50 mg/m² + paclitaxel 175 mg/m² or 135 mg/m² ± BEV 15 mg/kg q3w or paclitaxel 175 mg/m² + topotecan 0.75 mg/m² d1–d3 ± BEV 15 mg/kg q3w</td>
<td>25% 0% 0% 8%</td>
<td>Recurrent, persistent, or metastatic cervical cancer/452</td>
<td>RR: 48% (BEV + chemotherapy) versus 36% (chemotherapy alone)</td>
<td>(Continued)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Phase/regimen</th>
<th>HTN Grades 3 and 4</th>
<th>CHF Grades 3 and 4</th>
<th>ATEs Grades 3 and 4</th>
<th>VTEs Grades 3 and 4</th>
<th>Disease setting/number of patients</th>
<th>Efficacy results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>II/Capecitabine</td>
<td>17.9%</td>
<td>0%</td>
<td>0%</td>
<td>5.6%</td>
<td>Metastatic breast cancer</td>
<td>RR: 19.8% (capecitabine/BEV) versus 9.1% (capecitabine)</td>
<td>Miller et al56</td>
</tr>
<tr>
<td>Meta-analysis (19 randomized trials)</td>
<td>8%</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Colorectal, breast, renal cell, NSCLC, pancreatic cancer, malignant mesothelioma/12,949</td>
<td>Significant increase of BP in patients receiving BEV; renal cell cancer and breast cancer patients: higher risk, dose-limiting relationship</td>
<td>An et al36</td>
</tr>
<tr>
<td>Meta-analysis (15 randomized trials)</td>
<td>3.04 risk ratio</td>
<td>NA</td>
<td>1.44 risk ratio</td>
<td>1.44 risk ratio</td>
<td>Metastatic colorectal/6,937</td>
<td>Predisposing factors: &gt;65 years of age; history of an ATE</td>
<td>Dai et al58</td>
</tr>
<tr>
<td>Meta-analysis (five randomized trials)</td>
<td>NA</td>
<td>NA</td>
<td>3.8% (BEV) versus 1.7% (chemotherapy); HR = 2</td>
<td>No increased risk</td>
<td>Colorectal, non-small-cell, and breast cancer/1,745</td>
<td>Increased risk of developing an ATE with BEV (HR =1.44); cardiac ischemia (HR =2.14); ischemic stroke (HR =1.37); increased risk of ATE in renal cell and colorectal cancer</td>
<td>Scappaticci et al63</td>
</tr>
<tr>
<td>Meta-analysis (20 randomized trials)</td>
<td>NA</td>
<td>NA</td>
<td>3.3%</td>
<td>NA</td>
<td>Colorectal, breast, renal cell, NSCLC, and pancreatic cancer/12,617</td>
<td>Elevated risk of ATE (HR =1.82); nonelavated risk for CHF (HR =0.97)</td>
<td>Ranpura et al64</td>
</tr>
<tr>
<td>Population-based cohort study</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>Metastatic colorectal cancer/6,803</td>
<td>Increased risk of VTE (risk rate =1.33)</td>
<td>Tsai et al65</td>
</tr>
<tr>
<td>Meta-analysis (15 randomized studies)</td>
<td>NA</td>
<td>NA</td>
<td>6.3%</td>
<td>NA</td>
<td>Colorectal, breast, renal cell, NSCLC, and pancreatic cancer/7,956</td>
<td>No increased risk of VTE Risk factors for VTE development: old age; poor PS; tumor type; baseline anticoagulant use; VTE history</td>
<td>Nalluri et al62</td>
</tr>
<tr>
<td>Meta-analysis (ten randomized studies)</td>
<td>NA</td>
<td>NA</td>
<td>10.9%</td>
<td>NA</td>
<td>Colorectal, breast, renal cell, NSCLC, and pancreatic cancer/6,055</td>
<td>No increased risk of VTE Risk factors for VTE development: old age; poor PS; tumor type; baseline anticoagulant use; VTE history</td>
<td>Hurwitz et al64</td>
</tr>
</tbody>
</table>

**Abbreviations:** BEV, bevacizumab; HTN, hypertension; CHF, chronic heart failure; ATE, arterial thromboembolic event; VTE, venous thromboembolic event; q2w, every 2 weeks; HCC, hepatocellular carcinoma; PFS, progression-free survival; OS, overall survival; q3w, every 3 weeks; PR, partial response; SD, stable disease; FOLFOX4, folinic acid, fluorouracil, and oxaliplatin; TTP, time to progression; od, once daily; d1, day 1; d15, day 15; q28d, every 28 days; mFOLFOX6, modified fluorouracil, leucovorin, and oxaliplatin; RR, response rate; d8, day 8; ORR, overall response rate; RT, radiotherapy; 5-FU, fluorouracil; bd, twice daily; w1, week 1; w5, week 5; IMRT, intensity-modulated radiation therapy; NSCLC, non-small-cell lung cancer; AUC, area under the curve; q4w, every 4 weeks; IFNa, interferon-alpha; NA, not available; BP, blood pressure; HR, hazard ratio; PS, performance status.
The responsible underlying mechanism remains unclear. It is well known that the characteristic feature of any ATE is the instability of atherosclerotic plaques and the associated activation of platelets. Bevacizumab might reduce anti-inflammatory effects of chronic VEGF exposure, leading to increased inflammation and atherosclerotic instability, and to subsequent plaque rupture and thrombus formation. Additionally, VEGF is important for the proliferation and repair of endothelial cells. Therefore, anti-VEGF therapy may decrease the regenerative capacity of endothelial cells in response to trauma, leading to endothelial cell dysfunction and exposing subendothelial collagen. As a result of subendothelial collagen exposure, the tissue factor is activated, increasing the risk of thrombosis. Finally, anti-VEGF therapy causes a reduction in nitric oxide and prostacyclin, as well as an increase in blood viscosity via the overproduction of erythropoietin, all of which comprise predisposing factors for increased risk of thromboembolic events.

A pooled analysis of five randomized trials in metastatic CRC, NSCLC, and breast cancer that involved a total of 1,745 patients, demonstrated a higher risk of developing an ATE (such as angina, myocardial or cerebral ischemia/infarct and arterial thrombosis) in patients treated with chemotherapy and bevacizumab, as compared to those treated with chemotherapy alone (3.8% vs 1.7% in the control group; \(P\leq0.05\); hazard ratio = 2). The absolute rate of developing an ATE was 5.5 events per 100 patient-years for patients receiving chemotherapy plus bevacizumab, as compared to 3.1 events per 100 patient-years for those receiving chemotherapy alone (relative rate [RR] = 1.8; 95% confidence interval [CI]: 0.94–3.33). When looking at myocardial infarction/angina specifically, the incidence was 1.5% versus 1% in the bevacizumab group as compared with the control group, respectively. Predisposing factors were found to be old age (\(>65\) years) and a history of an ATE. A more recent meta-analysis, which included 12,617 patients from 20 Phase II and III randomized controlled trials, had similar results, showing a significantly increased risk of ATEs in patients receiving bevacizumab, as compared to controls (RR = 1.44; 95% CI: 1.08–1.91). More specifically, bevacizumab was associated with a significantly increased risk of cardiac ischemia (RR = 2.14; 95% CI: 1.12–4.08), but not stroke (RR = 1.37; 95% CI: 0.67–2.79, \(P=0.39\)). Patients receiving bevacizumab had an overall incidence of all-grade ATEs of 3.3%, whereas the incidence of high-grade events was 2%. As opposed to bevacizumab-related HTN, a dose–effect relationship was not found for the risk of ATEs, which was similar for doses of 2.5 mg/kg/week and 5 mg/kg/week. Furthermore, the risk varied with the type of malignancy, with the highest risk of all-grade ATEs demonstrated in patients with CRC (6.1%; 95% CI: 4.4–8.5); bevacizumab significantly increased that risk (RR = 2.79; 95% CI: 1.42–5.49). On the other hand, in a recent observational study that involved 6,803 elderly patients with CRC, patients treated with bevacizumab had a modestly elevated risk of ATEs; however, this did not commonly produce a clinical impact when expressed in absolute terms (four additional ATE cases per 1,000 person-years).

In Phase II trials assessing bevacizumab in combination with other agents in head and neck cancer, cardiac ischemia was reported in one patient in two studies; another study showed a relatively high incidence of syncope (7%). In all studies mentioned, bevacizumab-associated ATEs were reported to occur at any time during therapy.

Patients with suspected cardiac ischemia should be managed according to the guidelines established by the ESC and ESMO. However, one major concern in cancer patients treated with bevacizumab is the use of antiplatelet and anticoagulant therapy, due to increased risk of bleeding. Currently, there are no guidelines or prospective studies that include such patients. However, in the previously mentioned meta-analysis, concomitant use of chemotherapy, bevacizumab, and aspirin did not substantially increase the risk of bleeding compared to the use of aspirin and chemotherapy alone, and aspirin-based prophylaxis for an ATE is recommended for all cancer patients at risk when these is no contraindication. Furthermore, aspirin use has been shown to improve survival in cancer patients with cardiac ischemia, irrespective of thrombocytopenia. On the other hand, because studies excluded patients who had any history of stroke or myocardial infarction within 12 months of enrollment, the risks and benefits of bevacizumab treatment among these patients have not been established. Bevacizumab therapy should be discontinued in patients who develop severe ATEs during treatment; the safety of restarting bevacizumab therapy after resolution of an ATE has not yet been studied.

**Venous thromboembolic events (VTEs)**

The role of bevacizumab in the development of VTEs is controversial. In initial Phase II and Phase III clinical trials, the reported incidence of VTEs varied from 3%–19.4%. Several other Phase III randomized trials revealed a higher risk of VTEs associated with bevacizumab, although this was not statistically significant compared to controls.

In the previously mentioned meta-analysis by Scappaticci et al, bevacizumab therapy did not alter the risk of a VTE, and based on those results, venous thromboembolism was
not considered a major adverse event of bevacizumab. However, a meta-analysis conducted in 2008 that included 7,956 patients from 15 randomized trials with a variety of solid tumors (breast, colorectal, non-small-cell lung, renal cell, and other cancers) identified a significantly elevated risk of VTEs associated with bevacizumab therapy (RR=1.33; 95% CI: 1.13–1.56; P<0.001); this risk was observed in all-grade and high-grade VTEs. Similar to ATEs, the incidence of bevacizumab-related VTEs did not have a dose–effect relationship. A higher risk was found in lung cancer. This meta-analysis received criticism mainly focused on the fact that it was based on summary rates than on individual patient data, and there was no adjustment for differential observational times. A more recent meta-analysis, which assessed the role of bevacizumab in VTE development, included 6,055 patients from ten randomized trials. No significant increase in the risk of VTE associated with bevacizumab was found, and the lack of VTE risk was consistent with all tumor types. The reason for the disagreement between those two meta-analyses is probably due to differences in the included trials and analytic methods.

Similar to bevacizumab-induced arterial thrombosis, a possible related mechanism for bevacizumab-related VTEs might be the anti-VEGF effect of bevacizumab. VEGF is a protective factor for endothelial cells, regulating multiple biological functions such as the production of vasoactive mediators and the expression of components of the thrombolytic and coagulation pathways. The disturbance of vascular homeostasis by blocking VEGF might lead to endothelial dysfunction and subsequent VTEs. Furthermore, bevacizumab may increase the release of proinflammatory cytokines, causing activation of the clotting system. However, the difference in the bevacizumab-related risk of ATEs and VTEs also implies differences in pathophysiology.

Cancer patients who develop a VTE should be treated according to guidelines recommended by the ESMO. As in noncancer patients, low molecular weight heparin (LMWH) should be initiated at a dose of 200 U/kg once daily or 100 U/kg twice daily for 5–7 days. However, in cancer patients, continuation of LMWH, instead of substitution with vitamin K antagonists, has been proven beneficial. The majority of patients treated with bevacizumab suffer from metastatic cancer; for those patients, indefinite treatment with LMWH at a dose of 75%–80% of the initial dose is recommended.

**Adjunctive effect of radiotherapy**

It has been proposed that the combination of antiangiogenesis agents with radiotherapy might have a synergistic effect through several mechanisms. Antiangiogenesis inhibitors improve intratumoral oxygenation through normalization of intratumoral vasculature after radiation treatment, leading to increased blood perfusion and distribution of chemotherapy within the tumor; furthermore, improved oxygenation of the tumor induces the generation of reaction oxygen species that damage DNA and interact with the cell membrane to trigger apoptosis. In addition, treatment with antiangiogenesis agents downregulates growth factors, such as VEGF and EGF that have been shown to mediate radioresistance. In several clinical trials, the adjunctive effect of radiotherapy to angiogenesis inhibitors has been shown to increase toxicity. In a recent Phase III trial evaluating the use of bevacizumab in combination with radiotherapy and temozolomide for the treatment of newly diagnosed glioblastoma, the incidence rates of both HTN and ATEs were higher in the bevacizumab–radiation arm compared to the control arm (39.3% vs 12.7% and 5.9% vs 1.6%, respectively). On the other hand, the addition of bevacizumab to radiotherapy in Phase II head and neck and cervical cancer clinical trials has not been shown to exacerbate cardiotoxicity.

**Conclusion**

Through the years, the discovery of novel active antineoplastic agents has dramatically increased the survival of cancer patients, albeit while increasing the incidence of adverse events induced by anticancer treatment. Cardiovascular toxicity in oncology patients is an issue of major importance, particularly because of the diversity of mechanisms involved and the lack of specific treatment guidelines. Bevacizumab, a monoclonal human antibody directed against VEGF, has emerged as a powerful tool in many malignancies, but it has been associated with a variety of cardiac events. On the other hand, several other molecular targeted therapies, such as trastuzumab, as well as traditional chemotherapy drugs, such as anthracyclines, can also cause significant cardiotoxicity. Early recognition of cardiac complications and successful management of these disorders in order to increase the safety of anticancer treatments requires close cooperation of cardiology and oncology specialists.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


59. Murray JJ, Adamopoulos S, Anker SD, et al; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–869.


